Skip to main content
NCBI home page
Philosophical Transactions of the Royal Society B: Biological Sciences logoLink to Philosophical Transactions of the Royal Society B: Biological Sciences
. 2001 Apr 29;356(1408):475–488. doi: 10.1098/rstb.2000.0784

The immunology of Epstein-Barr virus infection.

D J Moss 1, S R Burrows 1, S L Silins 1, I Misko 1, R Khanna 1
PMCID: PMC1088439  PMID: 11313006

Abstract

Epstein-Barr virus is a classic example of a persistent human virus that has caught the imagination of immunologists, virologists and oncologists because of the juxtaposition of a number of important properties. First, the ability of the virus to immortalize B lymphocytes in vitro has provided an antigen presenting cell in which all the latent antigens of the virus are displayed and are available for systematic study. Second, the virus presents an ideal system for studying the immune parameters that maintain latency and the consequences of disturbing this cell-virus relationship. Third, this wealth of immunological background has provided a platform for elucidating the role of the immune system in protection from viral-associated malignancies of B cell and epithelial cell origin. Finally, attention is now being directed towards the development of vaccine formulations which might have broad application in the control of human malignancies.

Full Text

The Full Text of this article is available as a PDF (514.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ambinder R. F., Robertson K. D., Tao Q. DNA methylation and the Epstein-Barr virus. Semin Cancer Biol. 1999 Oct;9(5):369–375. doi: 10.1006/scbi.1999.0137. [DOI] [PubMed] [Google Scholar]
  2. Apolloni A., Moss D., Stumm R., Burrows S., Suhrbier A., Misko I., Schmidt C., Sculley T. Sequence variation of cytotoxic T cell epitopes in different isolates of Epstein-Barr virus. Eur J Immunol. 1992 Jan;22(1):183–189. doi: 10.1002/eji.1830220127. [DOI] [PubMed] [Google Scholar]
  3. Argaet V. P., Schmidt C. W., Burrows S. R., Silins S. L., Kurilla M. G., Doolan D. L., Suhrbier A., Moss D. J., Kieff E., Sculley T. B. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med. 1994 Dec 1;180(6):2335–2340. doi: 10.1084/jem.180.6.2335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Babcock G. J., Decker L. L., Volk M., Thorley-Lawson D. A. EBV persistence in memory B cells in vivo. Immunity. 1998 Sep;9(3):395–404. doi: 10.1016/s1074-7613(00)80622-6. [DOI] [PubMed] [Google Scholar]
  5. Blake N., Lee S., Redchenko I., Thomas W., Steven N., Leese A., Steigerwald-Mullen P., Kurilla M. G., Frappier L., Rickinson A. Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity. 1997 Dec;7(6):791–802. doi: 10.1016/s1074-7613(00)80397-0. [DOI] [PubMed] [Google Scholar]
  6. Blue M. L., Daley J. F., Levine H., Schlossman S. F. Coexpression of T4 and T8 on peripheral blood T cells demonstrated by two-color fluorescence flow cytometry. J Immunol. 1985 Apr;134(4):2281–2286. [PubMed] [Google Scholar]
  7. Bogedain C., Wolf H., Modrow S., Stuber G., Jilg W. Specific cytotoxic T lymphocytes recognize the immediate-early transactivator Zta of Epstein-Barr virus. J Virol. 1995 Aug;69(8):4872–4879. doi: 10.1128/jvi.69.8.4872-4879.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Burrows J. M., Burrows S. R., Poulsen L. M., Sculley T. B., Moss D. J., Khanna R. Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J Virol. 1996 Apr;70(4):2490–2496. doi: 10.1128/jvi.70.4.2490-2496.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Burrows S. R., Gardner J., Khanna R., Steward T., Moss D. J., Rodda S., Suhrbier A. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J Gen Virol. 1994 Sep;75(Pt 9):2489–2493. doi: 10.1099/0022-1317-75-9-2489. [DOI] [PubMed] [Google Scholar]
  10. Burrows S. R., Khanna R., Burrows J. M., Moss D. J. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease. J Exp Med. 1994 Apr 1;179(4):1155–1161. doi: 10.1084/jem.179.4.1155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Burrows S. R., Misko I. S., Sculley T. B., Schmidt C., Moss D. J. An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants. J Virol. 1990 Aug;64(8):3974–3976. doi: 10.1128/jvi.64.8.3974-3976.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Burrows S. R., Sculley T. B., Misko I. S., Schmidt C., Moss D. J. An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3). J Exp Med. 1990 Jan 1;171(1):345–349. doi: 10.1084/jem.171.1.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Burrows S. R., Silins S. L., Cross S. M., Peh C. A., Rischmueller M., Burrows J. M., Elliott S. L., McCluskey J. Human leukocyte antigen phenotype imposes complex constraints on the antigen-specific cytotoxic T lymphocyte repertoire. Eur J Immunol. 1997 Jan;27(1):178–182. doi: 10.1002/eji.1830270126. [DOI] [PubMed] [Google Scholar]
  14. Burrows S. R., Silins S. L., Khanna R., Burrows J. M., Rischmueller M., McCluskey J., Moss D. J. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol. 1997 Jul;27(7):1726–1736. doi: 10.1002/eji.1830270720. [DOI] [PubMed] [Google Scholar]
  15. Burrows S. R., Silins S. L., Moss D. J., Khanna R., Misko I. S., Argaet V. P. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen. J Exp Med. 1995 Dec 1;182(6):1703–1715. doi: 10.1084/jem.182.6.1703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Callan M. F., Annels N., Steven N., Tan L., Wilson J., McMichael A. J., Rickinson A. B. T cell selection during the evolution of CD8+ T cell memory in vivo. Eur J Immunol. 1998 Dec;28(12):4382–4390. doi: 10.1002/(SICI)1521-4141(199812)28:12<4382::AID-IMMU4382>3.0.CO;2-Z. [DOI] [PubMed] [Google Scholar]
  17. Callan M. F., Steven N., Krausa P., Wilson J. D., Moss P. A., Gillespie G. M., Bell J. I., Rickinson A. B., McMichael A. J. Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nat Med. 1996 Aug;2(8):906–911. doi: 10.1038/nm0896-906. [DOI] [PubMed] [Google Scholar]
  18. Callan M. F., Tan L., Annels N., Ogg G. S., Wilson J. D., O'Callaghan C. A., Steven N., McMichael A. J., Rickinson A. B. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med. 1998 May 4;187(9):1395–1402. doi: 10.1084/jem.187.9.1395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Campos-Lima P. O., Levitsky V., Imreh M. P., Gavioli R., Masucci M. G. Epitope-dependent selection of highly restricted or diverse T cell receptor repertoires in response to persistent infection by Epstein-Barr virus. J Exp Med. 1997 Jul 7;186(1):83–89. doi: 10.1084/jem.186.1.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Carter R. L. Infectious mononucleosis: model for self-limiting lymphoproliferation. Lancet. 1975 Apr 12;1(7911):846–849. doi: 10.1016/s0140-6736(75)93014-7. [DOI] [PubMed] [Google Scholar]
  21. Chen Z. W., Kou Z. C., Lekutis C., Shen L., Zhou D., Halloran M., Li J., Sodroski J., Lee-Parritz D., Letvin N. L. T cell receptor V beta repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus. J Exp Med. 1995 Jul 1;182(1):21–31. doi: 10.1084/jem.182.1.21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Couedel C., Bodinier M., Peyrat M. A., Bonneville M., Davodeau F., Lang F. Selection and long-term persistence of reactive CTL clones during an EBV chronic response are determined by avidity, CD8 variable contribution compensating for differences in TCR affinities. J Immunol. 1999 Jun 1;162(11):6351–6358. [PubMed] [Google Scholar]
  23. Dardari R., Khyatti M., Benider A., Jouhadi H., Kahlain A., Cochet C., Mansouri A., El Gueddari B., Benslimane A., Joab I. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma. Int J Cancer. 2000 Apr 1;86(1):71–75. doi: 10.1002/(sici)1097-0215(20000401)86:1<71::aid-ijc11>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  24. Doxiadis I. I., Smits J. M., Schreuder G. M., Persijn G. G., van Houwelingen H. C., van Rood J. J., Claas F. H. Association between specific HLA combinations and probability of kidney allograft loss: the taboo concept. Lancet. 1996 Sep 28;348(9031):850–853. doi: 10.1016/s0140-6736(96)02296-9. [DOI] [PubMed] [Google Scholar]
  25. Fiorillo M. T., Maragno M., Butler R., Dupuis M. L., Sorrentino R. CD8(+) T-cell autoreactivity to an HLA-B27-restricted self-epitope correlates with ankylosing spondylitis. J Clin Invest. 2000 Jul;106(1):47–53. doi: 10.1172/JCI9295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Fox R. I., Chilton T., Scott S., Benton L., Howell F. V., Vaughan J. H. Potential role of Epstein-Barr virus in Sjögren's syndrome. Rheum Dis Clin North Am. 1987 Aug;13(2):275–292. [PubMed] [Google Scholar]
  27. Garcia K. C., Degano M., Pease L. R., Huang M., Peterson P. A., Teyton L., Wilson I. A. Structural basis of plasticity in T cell receptor recognition of a self peptide-MHC antigen. Science. 1998 Feb 20;279(5354):1166–1172. doi: 10.1126/science.279.5354.1166. [DOI] [PubMed] [Google Scholar]
  28. Goldrath A. W., Bevan M. J. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity. 1999 Aug;11(2):183–190. doi: 10.1016/s1074-7613(00)80093-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Gregory C. D., Murray R. J., Edwards C. F., Rickinson A. B. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med. 1988 Jun 1;167(6):1811–1824. doi: 10.1084/jem.167.6.1811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Hammarskjöld M. L., Simurda M. C. Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. J Virol. 1992 Nov;66(11):6496–6501. doi: 10.1128/jvi.66.11.6496-6501.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Hemmer B., Vergelli M., Pinilla C., Houghten R., Martin R. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol Today. 1998 Apr;19(4):163–168. doi: 10.1016/s0167-5699(97)01217-6. [DOI] [PubMed] [Google Scholar]
  32. Henie G., Henle W., Horwitz C. A. Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis. J Infect Dis. 1974 Sep;130(3):231–239. doi: 10.1093/infdis/130.3.231. [DOI] [PubMed] [Google Scholar]
  33. Henle G., Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976 Jan 15;17(1):1–7. doi: 10.1002/ijc.2910170102. [DOI] [PubMed] [Google Scholar]
  34. Henle G., Lennette E. T., Alspaugh M. A., Henle W. Rheumatoid factor as a cause of positive reactions in tests for Epstein-Barr virus-specific IgM antibodies. Clin Exp Immunol. 1979 Jun;36(3):415–422. [PMC free article] [PubMed] [Google Scholar]
  35. Henle W., Henle G., Andersson J., Ernberg I., Klein G., Horwitz C. A., Marklund G., Rymo L., Wellinder C., Straus S. E. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci U S A. 1987 Jan;84(2):570–574. doi: 10.1073/pnas.84.2.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Heslop H. E., Rooney C. M. Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev. 1997 Jun;157:217–222. doi: 10.1111/j.1600-065x.1997.tb00984.x. [DOI] [PubMed] [Google Scholar]
  37. Hoffman G. J., Lazarowitz S. G., Hayward S. D. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci U S A. 1980 May;77(5):2979–2983. doi: 10.1073/pnas.77.5.2979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Khanna R., Burrows S. R., Argaet V., Moss D. J. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int Immunol. 1994 Apr;6(4):639–645. doi: 10.1093/intimm/6.4.639. [DOI] [PubMed] [Google Scholar]
  39. Khanna R., Burrows S. R., Kurilla M. G., Jacob C. A., Misko I. S., Sculley T. B., Kieff E., Moss D. J. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med. 1992 Jul 1;176(1):169–176. doi: 10.1084/jem.176.1.169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Khanna R., Burrows S. R., Moss D. J. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev. 1995 Sep;59(3):387–405. doi: 10.1128/mr.59.3.387-405.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Khanna R., Burrows S. R., Moss D. J., Silins S. L. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J Virol. 1996 Aug;70(8):5357–5362. doi: 10.1128/jvi.70.8.5357-5362.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Khanna R., Burrows S. R., Nicholls J., Poulsen L. M. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol. 1998 Feb;28(2):451–458. doi: 10.1002/(SICI)1521-4141(199802)28:02<451::AID-IMMU451>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  43. Khanna R., Busson P., Burrows S. R., Raffoux C., Moss D. J., Nicholls J. M., Cooper L. Molecular characterization of antigen-processing function in nasopharyngeal carcinoma (NPC): evidence for efficient presentation of Epstein-Barr virus cytotoxic T-cell epitopes by NPC cells. Cancer Res. 1998 Jan 15;58(2):310–314. [PubMed] [Google Scholar]
  44. Khanna R., Cooper L., Kienzle N., Moss D. J., Burrows S. R., Khanna K. K. Engagement of CD40 antigen with soluble CD40 ligand up-regulates peptide transporter expression and restores endogenous processing function in Burkitt's lymphoma cells. J Immunol. 1997 Dec 15;159(12):5782–5785. [PubMed] [Google Scholar]
  45. Khanna R., Sherritt M., Burrows S. R. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol. 1999 Mar 1;162(5):3063–3069. [PubMed] [Google Scholar]
  46. Khanna R., Slade R. W., Poulsen L., Moss D. J., Burrows S. R., Nicholls J., Burrows J. M. Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographical origins: evidence for immune pressure-independent genetic drift. J Virol. 1997 Nov;71(11):8340–8346. doi: 10.1128/jvi.71.11.8340-8346.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Khatri V. P., Baiocchi R. A., Peng R., Oberkircher A. R., Dolce J. M., Ward P. M., Herzig G. P., Caligiuri M. A. Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. J Immunol. 1999 Jul 1;163(1):500–506. [PubMed] [Google Scholar]
  48. Laherty C. D., Hu H. M., Opipari A. W., Wang F., Dixit V. M. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem. 1992 Dec 5;267(34):24157–24160. [PubMed] [Google Scholar]
  49. Lechler R. I., Lombardi G., Batchelor J. R., Reinsmoen N., Bach F. H. The molecular basis of alloreactivity. Immunol Today. 1990 Mar;11(3):83–88. doi: 10.1016/0167-5699(90)90033-6. [DOI] [PubMed] [Google Scholar]
  50. Lee S. P., Constandinou C. M., Thomas W. A., Croom-Carter D., Blake N. W., Murray P. G., Crocker J., Rickinson A. B. Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition. Blood. 1998 Aug 1;92(3):1020–1030. [PubMed] [Google Scholar]
  51. Lee S. P., Morgan S., Skinner J., Thomas W. A., Jones S. R., Sutton J., Khanna R., Whittle H. C., Rickinson A. B. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population. Eur J Immunol. 1995 Jan;25(1):102–110. doi: 10.1002/eji.1830250119. [DOI] [PubMed] [Google Scholar]
  52. Levitskaya J., Coram M., Levitsky V., Imreh S., Steigerwald-Mullen P. M., Klein G., Kurilla M. G., Masucci M. G. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 1995 Jun 22;375(6533):685–688. doi: 10.1038/375685a0. [DOI] [PubMed] [Google Scholar]
  53. Levitsky V., de Campos-Lima P. O., Frisan T., Masucci M. G. The clonal composition of a peptide-specific oligoclonal CTL repertoire selected in response to persistent EBV infection is stable over time. J Immunol. 1998 Jul 15;161(2):594–601. [PubMed] [Google Scholar]
  54. Maruya E., Takemoto S., Terasaki P. I. HLA matching: identification of permissible HLA mismatches. Clin Transpl. 1993:511–520. [PubMed] [Google Scholar]
  55. Mason D. A very high level of crossreactivity is an essential feature of the T-cell receptor. Immunol Today. 1998 Sep;19(9):395–404. doi: 10.1016/s0167-5699(98)01299-7. [DOI] [PubMed] [Google Scholar]
  56. Misko I. S., Cross S. M., Khanna R., Elliott S. L., Schmidt C., Pye S. J., Silins S. L. Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: implications for molecular mimicry in autoimmune disease. Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2279–2284. doi: 10.1073/pnas.96.5.2279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Misko I. S., Kane R. G., Pope J. H. Restriction of foetal calf serum-induced cytotoxicity by human T-cells. Immunol Lett. 1981 Jun;3(2):81–85. doi: 10.1016/0165-2478(81)90055-9. [DOI] [PubMed] [Google Scholar]
  58. Misko I. S., Moss D. J., Pope J. H. HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus. Proc Natl Acad Sci U S A. 1980 Jul;77(7):4247–4250. doi: 10.1073/pnas.77.7.4247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Misko I. S., Pope J. H., Hütter R., Soszynski T. D., Kane R. G. HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies. Int J Cancer. 1984 Feb 15;33(2):239–243. doi: 10.1002/ijc.2910330212. [DOI] [PubMed] [Google Scholar]
  60. Miyashita E. M., Yang B., Babcock G. J., Thorley-Lawson D. A. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol. 1997 Jul;71(7):4882–4891. doi: 10.1128/jvi.71.7.4882-4891.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Moghaddam A., Rosenzweig M., Lee-Parritz D., Annis B., Johnson R. P., Wang F. An animal model for acute and persistent Epstein-Barr virus infection. Science. 1997 Jun 27;276(5321):2030–2033. doi: 10.1126/science.276.5321.2030. [DOI] [PubMed] [Google Scholar]
  62. Morgan A. J. Epstein-Barr virus vaccines. Vaccine. 1992;10(9):563–571. doi: 10.1016/0264-410x(92)90434-l. [DOI] [PubMed] [Google Scholar]
  63. Moss D. J., Bishop C. J., Burrows S. R., Ryan J. M. T lymphocytes in infectious mononucleosis. I. T cell death in vitro. Clin Exp Immunol. 1985 Apr;60(1):61–69. [PMC free article] [PubMed] [Google Scholar]
  64. Moss D. J., Chan S. H., Burrows S. R., Chew T. S., Kane R. G., Staples J. A., Kunaratnam N. Epstein-Barr virus specific T-cell response in nasopharyngeal carcinoma patients. Int J Cancer. 1983 Sep 15;32(3):301–305. doi: 10.1002/ijc.2910320307. [DOI] [PubMed] [Google Scholar]
  65. Moss D. J., Misko I. S., Burrows S. R., Burman K., McCarthy R., Sculley T. B. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature. 1988 Feb 25;331(6158):719–721. doi: 10.1038/331719a0. [DOI] [PubMed] [Google Scholar]
  66. Moss D. J., Rickinson A. B., Pope J. H. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes. Int J Cancer. 1978 Dec;22(6):662–668. doi: 10.1002/ijc.2910220604. [DOI] [PubMed] [Google Scholar]
  67. Nahill S. R., Welsh R. M. High frequency of cross-reactive cytotoxic T lymphocytes elicited during the virus-induced polyclonal cytotoxic T lymphocyte response. J Exp Med. 1993 Feb 1;177(2):317–327. doi: 10.1084/jem.177.2.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Pantaleo G., Demarest J. F., Schacker T., Vaccarezza M., Cohen O. J., Daucher M., Graziosi C., Schnittman S. S., Quinn T. C., Shaw G. M. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):254–258. doi: 10.1073/pnas.94.1.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Pantaleo G., Demarest J. F., Soudeyns H., Graziosi C., Denis F., Adelsberger J. W., Borrow P., Saag M. S., Shaw G. M., Sekaly R. P. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature. 1994 Aug 11;370(6489):463–467. doi: 10.1038/370463a0. [DOI] [PubMed] [Google Scholar]
  70. Pepperl S., Benninger-Döring G., Modrow S., Wolf H., Jilg W. Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. J Virol. 1998 Nov;72(11):8644–8649. doi: 10.1128/jvi.72.11.8644-8649.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Pothen S., Richert J. R., Pearson G. R. Human T-cell recognition of Epstein-Barr virus-induced replication antigen complexes. Int J Cancer. 1991 Nov 11;49(5):656–660. doi: 10.1002/ijc.2910490505. [DOI] [PubMed] [Google Scholar]
  72. Pouteil-Noble C., Ecochard R., Landrivon G., Donia-Maged A., Tardy J. C., Bosshard S., Colon S., Betuel H., Aymard M., Touraine J. L. Cytomegalovirus infection--an etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation. 1993 Apr;55(4):851–857. doi: 10.1097/00007890-199304000-00032. [DOI] [PubMed] [Google Scholar]
  73. Qualtiere L. F., Chase R., Pearson G. R. Purification and biologic characterization of a major Epstein Barr virus-induced membrane glycoprotein. J Immunol. 1982 Aug;129(2):814–818. [PubMed] [Google Scholar]
  74. Rickinson A. B., Moss D. J. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405–431. doi: 10.1146/annurev.immunol.15.1.405. [DOI] [PubMed] [Google Scholar]
  75. Rickinson A. B., Moss D. J., Pope J. H. Long-term C-cell-mediated immunity to Epstein-Barr virus in man. II. Components necessary for regression in virus-infected leukocyte cultures. Int J Cancer. 1979 May 15;23(5):610–617. doi: 10.1002/ijc.2910230505. [DOI] [PubMed] [Google Scholar]
  76. Rooney C. M., Rowe M., Wallace L. E., Rickinson A. B. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature. 1985 Oct 17;317(6038):629–631. doi: 10.1038/317629a0. [DOI] [PubMed] [Google Scholar]
  77. Roskrow M. A., Suzuki N., Gan Y. j., Sixbey J. W., Ng C. Y., Kimbrough S., Hudson M., Brenner M. K., Heslop H. E., Rooney C. M. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 1998 Apr 15;91(8):2925–2934. [PubMed] [Google Scholar]
  78. Royston I., Sullivan J. L., Periman P. O., Perlin E. Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis. N Engl J Med. 1975 Dec 4;293(23):1159–1163. doi: 10.1056/NEJM197512042932301. [DOI] [PubMed] [Google Scholar]
  79. Saal J. G., Krimmel M., Steidle M., Gerneth F., Wagner S., Fritz P., Koch S., Zacher J., Sell S., Einsele H. Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis Rheum. 1999 Jul;42(7):1485–1496. doi: 10.1002/1529-0131(199907)42:7<1485::AID-ANR24>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  80. Schmidt C. W., Misko I. S. The ecology and pathology of Epstein-Barr virus. Immunol Cell Biol. 1995 Dec;73(6):489–504. doi: 10.1038/icb.1995.79. [DOI] [PubMed] [Google Scholar]
  81. Sculley T. B., Apolloni A., Hurren L., Moss D. J., Cooper D. A. Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis. 1990 Sep;162(3):643–648. doi: 10.1093/infdis/162.3.642. [DOI] [PubMed] [Google Scholar]
  82. Sharrock C. E., Kaminski E., Man S. Limiting dilution analysis of human T cells: a useful clinical tool. Immunol Today. 1990 Aug;11(8):281–286. doi: 10.1016/0167-5699(90)90113-n. [DOI] [PubMed] [Google Scholar]
  83. Sherman L. A., Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol. 1993;11:385–402. doi: 10.1146/annurev.iy.11.040193.002125. [DOI] [PubMed] [Google Scholar]
  84. Shimakage M., Dezawa T., Chatani M. Proper use of serum antibody titres against Epstein-Barr virus in nasopharyngeal carcinoma: IgA/virus capsid antigen for diagnosis and EBV-related nuclear antigen-2 for follow-up. Acta Otolaryngol. 2000 Jan;120(1):100–104. doi: 10.1080/00016480060203325. [DOI] [PubMed] [Google Scholar]
  85. Silins S. L., Cross S. M., Elliott S. L., Pye S. J., Burrows J. M., Moss D. J., Misko I. S. Selection of a diverse TCR repertoire in response to an Epstein-Barr virus-encoded transactivator protein BZLF1 by CD8+ cytotoxic T lymphocytes during primary and persistent infection. Int Immunol. 1997 Nov;9(11):1745–1755. doi: 10.1093/intimm/9.11.1745. [DOI] [PubMed] [Google Scholar]
  86. Silins S. L., Cross S. M., Elliott S. L., Pye S. J., Burrows S. R., Burrows J. M., Moss D. J., Argaet V. P., Misko I. S. Development of Epstein-Barr virus-specific memory T cell receptor clonotypes in acute infectious mononucleosis. J Exp Med. 1996 Nov 1;184(5):1815–1824. doi: 10.1084/jem.184.5.1815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Silins S. L., Cross S. M., Krauer K. G., Moss D. J., Schmidt C. W., Misko I. S. A functional link for major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection. J Clin Invest. 1998 Oct 15;102(8):1551–1558. doi: 10.1172/JCI4225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Sixbey J. W., Shirley P., Chesney P. J., Buntin D. M., Resnick L. Detection of a second widespread strain of Epstein-Barr virus. Lancet. 1989 Sep 30;2(8666):761–765. doi: 10.1016/s0140-6736(89)90829-5. [DOI] [PubMed] [Google Scholar]
  89. Smith T. J., Terada N., Robinson C. C., Gelfand E. W. Acute infectious mononucleosis stimulates the selective expression/expansion of V beta 6.1-3 and V beta 7 T cells. Blood. 1993 Mar 15;81(6):1521–1526. [PubMed] [Google Scholar]
  90. Sourdive D. J., Murali-Krishna K., Altman J. D., Zajac A. J., Whitmire J. K., Pannetier C., Kourilsky P., Evavold B., Sette A., Ahmed R. Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J Exp Med. 1998 Jul 6;188(1):71–82. doi: 10.1084/jem.188.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Steven N. M., Annels N. E., Kumar A., Leese A. M., Kurilla M. G., Rickinson A. B. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med. 1997 May 5;185(9):1605–1617. doi: 10.1084/jem.185.9.1605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  92. Strang G., Rickinson A. B. Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis. Eur J Immunol. 1987 Jul;17(7):1007–1013. doi: 10.1002/eji.1830170717. [DOI] [PubMed] [Google Scholar]
  93. Sutkowski N., Palkama T., Ciurli C., Sekaly R. P., Thorley-Lawson D. A., Huber B. T. An Epstein-Barr virus-associated superantigen. J Exp Med. 1996 Sep 1;184(3):971–980. doi: 10.1084/jem.184.3.971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Svedmyr E., Jondal M. Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1622–1626. doi: 10.1073/pnas.72.4.1622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Tan L. C., Gudgeon N., Annels N. E., Hansasuta P., O'Callaghan C. A., Rowland-Jones S., McMichael A. J., Rickinson A. B., Callan M. F. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol. 1999 Feb 1;162(3):1827–1835. [PubMed] [Google Scholar]
  96. Than S., Kharbanda M., Chitnis V., Bakshi S., Gregersen P. K., Pahwa S. Clonal dominance patterns of CD8 T cells in relation to disease progression in HIV-infected children. J Immunol. 1999 Mar 15;162(6):3680–3686. [PubMed] [Google Scholar]
  97. Thomson S. A., Elliott S. L., Sherritt M. A., Sproat K. W., Coupar B. E., Scalzo A. A., Forbes C. A., Ladhams A. M., Mo X. Y., Tripp R. A. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J Immunol. 1996 Jul 15;157(2):822–826. [PubMed] [Google Scholar]
  98. Thomson S. A., Khanna R., Gardner J., Burrows S. R., Coupar B., Moss D. J., Suhrbier A. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5845–5849. doi: 10.1073/pnas.92.13.5845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. Thorley-Lawson D. A., Babcock G. J. A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life Sci. 1999;65(14):1433–1453. doi: 10.1016/s0024-3205(99)00214-3. [DOI] [PubMed] [Google Scholar]
  100. Thorley-Lawson D. A., Geilinger K. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci U S A. 1980 Sep;77(9):5307–5311. doi: 10.1073/pnas.77.9.5307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Tierney R. J., Steven N., Young L. S., Rickinson A. B. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol. 1994 Nov;68(11):7374–7385. doi: 10.1128/jvi.68.11.7374-7385.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Torsteinsdottir S., Brautbar C., Klein G., Klein E., Masucci M. G. Differential expression of HLA antigens on human B-cell lines of normal and malignant origin: a consequence of immune surveillance or a phenotypic vestige of the progenitor cells? Int J Cancer. 1988 Jun 15;41(6):913–919. doi: 10.1002/ijc.2910410625. [DOI] [PubMed] [Google Scholar]
  103. Wang F., Gregory C., Sample C., Rowe M., Liebowitz D., Murray R., Rickinson A., Kieff E. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol. 1990 May;64(5):2309–2318. doi: 10.1128/jvi.64.5.2309-2318.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. White C. A., Cross S. M., Kurilla M. G., Kerr B. M., Schmidt C., Misko I. S., Khanna R., Moss D. J. Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1. Virology. 1996 May 15;219(2):489–492. doi: 10.1006/viro.1996.0277. [DOI] [PubMed] [Google Scholar]
  105. Wilson J. D., Cranage M., Cook N., Leech S., McMichael A. J., Callan M. F. Evidence for the persistence of monoclonal expansions of CD8+ T cells following primary simian immunodeficiency virus infection. Eur J Immunol. 1998 Apr;28(4):1172–1180. doi: 10.1002/(SICI)1521-4141(199804)28:04<1172::AID-IMMU1172>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  106. Xu J., Ahmad A., D'Addario M., Knafo L., Jones J. F., Prasad U., Dolcetti R., Vaccher E., Menezes J. Analysis and significance of anti-latent membrane protein-1 antibodies in the sera of patients with EBV-associated diseases. J Immunol. 2000 Mar 1;164(5):2815–2822. doi: 10.4049/jimmunol.164.5.2815. [DOI] [PubMed] [Google Scholar]
  107. Yoshizaki T., Miwa H., Takeshita H., Sato H., Furukawa M. Elevation of antibody against Epstein-Barr virus genes BRLF1 and BZLF1 in nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2000 Feb;126(2):69–73. [PubMed] [Google Scholar]
  108. de Campos-Lima P. O., Gavioli R., Zhang Q. J., Wallace L. E., Dolcetti R., Rowe M., Rickinson A. B., Masucci M. G. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science. 1993 Apr 2;260(5104):98–100. doi: 10.1126/science.7682013. [DOI] [PubMed] [Google Scholar]

Articles from Philosophical Transactions of the Royal Society of London. Series B are provided here courtesy of The Royal Society

RESOURCES